title: Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
abstract: OBJECTIVE
  A prospective evaluation of an ambulatory intraperitoneal (IP) /intravenous (IV) chemotherapy regimen for women with epithelial ovarian carcinoma (EOC).
  
  
  METHODS
  Cisplatin 100 mg/m(2) (option for 75 mg/m(2)) IP combined with paclitaxel 175 mg/m(2) IV (3 h infusion) administered every 21 days was adopted by our institution as a single day, outpatient regimen for women with stage III EOC who had undergone optimal cytoreductive (<or=1 cm) surgery. A prospective database including patient characteristics, toxicity (graded as per CTCAE-v 3.0) and time spent in the outpatient unit was established to follow patients receiving IP chemotherapy.
  
  
  RESULTS
  Between December 2005 and June 2008, 47 patients, median age 50 years (range 25-75) received a total of 238 cycles of IP/IV chemotherapy. The median number of cycles was 6 (range 1-6). 81% of patients (n=33) completed 6 planned cycles of treatment. Seven patients discontinued IP chemotherapy early due to catheter related complications (3) and chemotherapy toxicity (4). The most common grade 3 adverse events were abdominal pain (15%), nausea (15%), vomiting (13%), fatigue (11%) and peripherally neuropathy (9%). Residual peripheral neuropathy was reported at last follow up in 11 patients (grade 3 in 2). The median time spent in the chemotherapy unit was 7 h (range 6.5 to 9) per cycle.
  
  
  CONCLUSIONS
  Cisplatin 100 mg/m(2) IP combined with paclitaxel 175 mg/m(2) IV every 21 days is well tolerated and can be administered in an ambulatory chemotherapy unit. This regimen is convenient for patients and potentially more cost effective than other published IP cisplatin-based regimens.
authors.affiliation: Department of Medical Oncology, Princess Margaret Hospital, University of Toronto, 610 University Ave, Totonto, ON, Canada M5G 2M9.
authors.forename: Sheray N
authors.initials: SN
authors.lastname: Chin
authors.forename: Victoria
authors.initials: V
authors.lastname: Pinto
authors.forename: Barry
authors.initials: B
authors.lastname: Rosen
authors.forename: Amit
authors.initials: A
authors.lastname: Oza
authors.forename: Jason
authors.initials: J
authors.lastname: Dodge
authors.forename: Joan
authors.initials: J
authors.lastname: Murphy
authors.forename: Helen
authors.initials: H
authors.lastname: Mackay
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies
chemical_list: D017239:Paclitaxel; D002945:Cisplatin